Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523413 | 1.00 | CDK1 (0.67) | CDK1HDAC1NUDT1BRAFHTR2B | |
| SCHEMBL30523360 | 0.88 | HTR2B (0.52) | CDK1HDAC1HTR2BTMIGD3HTR2C | |
| SCHEMBL16145780 | 0.88 | HTR2B (0.52) | CDK1HDAC1HTR2BTMIGD3HTR2C | |
| SCHEMBL16145921 | 0.86 | CDK1 (0.76) | CDK1HDAC1NUDT1BRAFHTR2B | |
| SCHEMBL16145860 | 0.85 | MAPT (0.51) | CDK1HDAC1HTR2BTMIGD3HTR2C | |
| SCHEMBL30523435 | 0.85 | MAPT (0.51) | CDK1HDAC1HTR2BTMIGD3HTR2C | |
| SCHEMBL27587370 | 0.84 | CDK1 (0.73) | CDK1HDAC1NUDT1BRAFHTR2B | |
| SCHEMBL16147160 | 0.81 | ALPL (0.50) | CDK1HTR2BTMIGD3HTR2CMAPT | |
| SCHEMBL16145983 | 0.81 | ARG1 (0.46) | CDK1HDAC1 | |
| SCHEMBL16146406 | 0.81 | CDK1 (0.76) | CDK1HDAC1NUDT1BRAFHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CDK1 2235/4885HDAC1 473/4885NUDT1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.